Session: MON 327-337-Neuroendocrine Tumors
Poster Board MON-331
Matherials and methods: we treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, progressive, low or intermediate-grade NETs for a mean period of 11 months. Somatostatin analogues treatment was continued in all patients. 12/14 patients had previously undergone Peptide Receptor Radionuclide Therapy (PRRT).
Results: according to RECIST criteria, stable disease was observed in 9/14 patients and partial response was achieved in 2/14 patients. Median progression-free survival was 12.0 months. Drug-related adverse events included stomatitis (7/14), hyperglycaemia (7/14), hypertriglyceridemia (5/14), pneumonitis (4/14), hematologic toxicity (4/14), peripheral oedema (4/14) and rash (2/14). Grade 3 and 4 adverse events included pneumonitis (3 cases) and thrombocytopenia (2 cases). Dose reduction was required in 5/14 patients.
Conclusion: our data confirm the efficacy of everolimus in the treatment of progressive, advanced NETs. The apparently higher rate of grade 3 and 4 adverse events is probably related to the high proportion of patients in our series that had previously undergone PRRT, as it may enhance everolimus potential mielotoxicity.
Nothing to Disclose: DI, FL, FP, RB, GS, AB, GR, AP, LD, CAMB
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters